0

Close
 
Upcoming Allied Market Research
2023
Non-invasive Prenatal Testing (nipt) Market

Non-Invasive Prenatal Testing (NIPT) Market

by Product (Consumables, Instruments), by Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests), by Application (Trisomy, Microdeletion Syndrome, Other Applications) and by End User (Diagnostic Laboratories, Hospitals): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A02373
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Non-invasive Prenatal Testing (nipt) Market

Request Now !

Non-invasive prenatal testing is also known as non-invasive parenteral screening, which is a nascent genetic process of examining a fetal cell free DNA present in the mothers blood serum for detecting common fetal aneuploidies. Its main objective is early detection of genetic disorders such as trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). It can also detect the blood group and rhesus actor of the fetus. Some of the NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panorama, NIFTY, PrenaTest, BambniTest, and others.

Growth in reimbursements for the NIPT sector, increased shift from invasive methods to non-invasive methods, and growth of maternal age (associated with growth in the risk of chromosomal abnormalities in babies) drive the market. In addition, launch and development of advanced and new technologies and non-invasive parenteral testing products also fuels the market growth. However, lack of skilled professionals as well as strict regulatory guidelines and ethical hurdles slow down the process of approvals and marketing, thus restricting the market growth. Untapped emergence of new market in Asia-Pacific make way for growth opportunities for his market.

The report segments the market on the basis of product, method, application, end users, and region. Based on product, it is bifurcated into consumables and instruments. Based on method, it is divided into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, and fetal cells in maternal blood tests. Based on application, it can be categorized into trisomy, microdeletion syndrome, and other applications. By geography, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The key players of non-invasive parenteral testing market are Ge Healthcare (General Electric Company), Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.

Key Benefits

  • The study provides an in-depth analysis of the non-invasive prenatal testing market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates various forms of non-invasive prenatal testing available.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

 Non-Invasive Prenatal Testing (NIPT) Market Report Highlights

Aspects Details
By Product
  • Consumables
    • Assay Kits & Reagents
    • Disposables
  • Instruments
    • Ultrasound Devices
    • Next-Generation Sequencing Systems
    • Polymerase Chain Reaction Instruments
    • Microarrays
    • Other Instruments
By Method
  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-Free DNA in Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests
By Application
  • Trisomy
  • Microdeletion Syndrome
  • Other Applications
By End User
  • Diagnostic Laboratories
  • Hospitals
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GE Healthcare (General Electric Company), Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc., Koninklijke Philips N.V., F. Hoffman-La Roche Ltd., Beijing Genomics Institute, Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Qiagen N.V.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Assay Kits Reagents

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Disposables

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Ultrasound Devices

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Next-Generation Sequencing Systems

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Polymerase Chain Reaction Instruments

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Microarrays

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Other Instruments

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY METHOD

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Method

    • 5.2. Ultrasound Detection

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Biochemical Screening Tests

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cell-Free DNA In Maternal Plasma Tests

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Fetal Cells In Maternal Blood Tests

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Trisomy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Microdeletion Syndrome

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Other Applications

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Diagnostic Laboratories

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Hospitals

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Method

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Non-invasive Prenatal Testing (nipt) Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Method
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Non-invasive Prenatal Testing (nipt) Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Method
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Non-invasive Prenatal Testing (nipt) Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Method
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Method

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Non-invasive Prenatal Testing (nipt) Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Method
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Non-invasive Prenatal Testing (nipt) Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Method
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Non-invasive Prenatal Testing (nipt) Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Method
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Non-invasive Prenatal Testing (nipt) Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Method
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Non-invasive Prenatal Testing (nipt) Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Method
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Non-invasive Prenatal Testing (nipt) Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Method
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Non-invasive Prenatal Testing (nipt) Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Method
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Method

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Non-invasive Prenatal Testing (nipt) Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Method
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Non-invasive Prenatal Testing (nipt) Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Method
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Non-invasive Prenatal Testing (nipt) Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Method
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Non-invasive Prenatal Testing (nipt) Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Method
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Non-invasive Prenatal Testing (nipt) Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Method
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Non-invasive Prenatal Testing (nipt) Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Method
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Non-invasive Prenatal Testing (nipt) Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Method
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Non-invasive Prenatal Testing (nipt) Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Method
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Non-invasive Prenatal Testing (nipt) Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Method
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Method

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Non-invasive Prenatal Testing (nipt) Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Method
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Non-invasive Prenatal Testing (nipt) Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Method
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Non-invasive Prenatal Testing (nipt) Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Method
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Non-invasive Prenatal Testing (nipt) Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Method
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Non-invasive Prenatal Testing (nipt) Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Method
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Non-invasive Prenatal Testing (nipt) Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Method
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. GE Healthcare (General Electric Company)

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Koninklijke Philips N.V.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Illumina, Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Thermo Fisher Scientific, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. F. Hoffman-La Roche Ltd.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Pacific Biosciences Of California, Inc.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Perkinelmer, Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Qiagen N.V.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Agilent Technologies, Inc.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Beijing Genomics Institute

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY METHOD, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR ULTRASOUND DETECTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR BIOCHEMICAL SCREENING TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR CELL-FREE DNA IN MATERNAL PLASMA TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR FETAL CELLS IN MATERNAL BLOOD TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR TRISOMY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR MICRODELETION SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. U.S. NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. U.S. NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 24. U.S. NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. U.S. NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. CANADA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. CANADA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 28. CANADA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. CANADA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. ITALY NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. ITALY NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 49. ITALY NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. ITALY NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. UK NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. UK NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 57. UK NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. UK NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. CHINA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. CHINA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 74. CHINA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. CHINA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. INDIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. INDIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 82. INDIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. INDIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 125. UAE NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 126. UAE NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 127. UAE NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 128. UAE NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY METHOD, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA NON-INVASIVE PRENATAL TESTING (NIPT), BY END USER, 2022-2032 ($MILLION)
  • TABLE 137. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): KEY EXECUTIVES
  • TABLE 138. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): COMPANY SNAPSHOT
  • TABLE 139. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): OPERATING SEGMENTS
  • TABLE 140. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): PRODUCT PORTFOLIO
  • TABLE 141. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 143. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 144. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 145. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 146. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 148. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 149. ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 150. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 151. ILLUMINA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 153. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 154. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 155. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 156. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. F. HOFFMAN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 158. F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 159. F. HOFFMAN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 160. F. HOFFMAN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 161. F. HOFFMAN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: KEY EXECUTIVES
  • TABLE 163. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY SNAPSHOT
  • TABLE 164. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: OPERATING SEGMENTS
  • TABLE 165. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: PRODUCT PORTFOLIO
  • TABLE 166. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. PERKINELMER, INC.: KEY EXECUTIVES
  • TABLE 168. PERKINELMER, INC.: COMPANY SNAPSHOT
  • TABLE 169. PERKINELMER, INC.: OPERATING SEGMENTS
  • TABLE 170. PERKINELMER, INC.: PRODUCT PORTFOLIO
  • TABLE 171. PERKINELMER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. QIAGEN N.V.: KEY EXECUTIVES
  • TABLE 173. QIAGEN N.V.: COMPANY SNAPSHOT
  • TABLE 174. QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 175. QIAGEN N.V.: PRODUCT PORTFOLIO
  • TABLE 176. QIAGEN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 178. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 179. AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 180. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 181. AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. BEIJING GENOMICS INSTITUTE: KEY EXECUTIVES
  • TABLE 183. BEIJING GENOMICS INSTITUTE: COMPANY SNAPSHOT
  • TABLE 184. BEIJING GENOMICS INSTITUTE: OPERATING SEGMENTS
  • TABLE 185. BEIJING GENOMICS INSTITUTE: PRODUCT PORTFOLIO
  • TABLE 186. BEIJING GENOMICS INSTITUTE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET
  • FIGURE 3. SEGMENTATION NON-INVASIVE PRENATAL TESTING (NIPT) MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NON-INVASIVE PRENATAL TESTING (NIPT) MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNON-INVASIVE PRENATAL TESTING (NIPT) MARKET
  • FIGURE 11. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION, BY BY METHOD
  • FIGURE 15. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR ULTRASOUND DETECTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR BIOCHEMICAL SCREENING TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR CELL-FREE DNA IN MATERNAL PLASMA TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR FETAL CELLS IN MATERNAL BLOOD TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 20. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR TRISOMY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR MICRODELETION SYNDROME, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION, BY BY END USER
  • FIGURE 24. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. NON-INVASIVE PRENATAL TESTING (NIPT) MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: NON-INVASIVE PRENATAL TESTING (NIPT) MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. GE HEALTHCARE (GENERAL ELECTRIC COMPANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ILLUMINA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ILLUMINA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ILLUMINA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. F. HOFFMAN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. F. HOFFMAN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. F. HOFFMAN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. PERKINELMER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. PERKINELMER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. PERKINELMER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. QIAGEN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. QIAGEN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. QIAGEN N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. AGILENT TECHNOLOGIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. BEIJING GENOMICS INSTITUTE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. BEIJING GENOMICS INSTITUTE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. BEIJING GENOMICS INSTITUTE: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Non-invasive Prenatal Testing (nipt) Market

Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers